Inventia Life Science’s Post

Have you seen our latest news? --> https://lnkd.in/d6EvYi7z Concarlo is taking a novel approach by targeting a central regulator in cell division, the protein p27. By doing so, Concarlo’s p27 inhibitor simultaneously controls multiple CDKs, effectively halting cancer cell growth and offering a more potent and durable treatment option. Concarlo’s latest study results illustrate that p27 inhibitors exhibit tolerability in vivo in mice and block growth of treatment naive, CDK4/6 inhibitor-resistant cells and enhanced the efficacy of established CDK4/6 inhibitors like palbociclib and ribociclib.

As one of the main factors driving non-small cell lung cancer, the KRAS G12C mutation has received much attention from clinicians. In America, there are two KRAS G12C inhibitor compounds approved by the FDA. On the contrary, Chinese clinicians and patients are still waiting for this kind of treatment option. At ASCO 2024, Professor Yuankai Shi presented his new phase II study results of Glecirasib, a Chinese-developed KRAS G12C inhibitor, showing satisfying clinical efficacy and a favorable safety profile. In the ‘Navigator Dialogue,’ Professor Shi shared some key points of the study and his confidence in the potential of the compound. 💉🔬 #LungCancer #KRASG12C #CancerResearch #ASCO2024 #MedicalBreakthrough

Check out Jacobio Pharma (SEHK:1167)'s updates at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting! The company presented updated data on their KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) for frontline non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutation. Professor Jun Zhao, chief physician of Beijing Cancer Hospital and principal investigator of the glecirasib combined with JAB-3312 study, shared compelling clinical data. Among 102 frontline NSCLC patients across 7 dose groups, the confirmed objective response rate (cORR) stood at 64.7%, with a disease control rate (DCR) of 93.1%. Moreover, the median progression-free survival (mPFS) clocked in at 12.2 months. #ASCO2024 #Oncology #ClinicalResearch #QimingHealthcare #QimingPortfolio 

Researchers have developed a new class of chimeric antigen receptors (CARs) called peptide-centric CARs (PC-CARs) to specifically target cancer-associated peptides. PC-CARs exhibit a unique attribute of HLA restriction, meaning their reactivity is dependent on the presentation of target peptides in the context of HLA molecules. This feature sets them apart from conventional CARs, which usually lack HLA restriction. PC-CARs possess the capability to target intracellular antigens, expanding the scope of potential therapeutic interventions in cancer treatment. Learn more about this exciting development in cancer research! #cancerresearch #CARtherapy #medicaladvancements

Examining the role of extracellular vesicles in ovarian cancer: in this review article, Barathan Muttiah, Nur Atiqah Haizum Abdullah at Universiti Kebangsaan Malaysia (UKM) and collaborators investigated the obstacles in ovarian cancer treatment, emphasising the mechanisms of chemoresistance and the potential of extracellular vesicles as effective drug delivery agents https://lnkd.in/e_zuV777 They highlighted key resistance mechanisms such as drug efflux, apoptosis disruption, enhanced DNA repair, cancer stem cells, immune evasion, and the intricacies of the tumour microenvironment. An article co-authored by Nur Dina Muhammad Fuad and Faizul Jaafar #extracellularvesicles #exosomes #ovariancancer #drugdelivery #Vesiculab

Jacobio Pharma 's Glecirasib (JAB-21822) is included in China's NMPA priority review. The treatment is intended for adult patients with localized advanced or metastatic non-small cell lung cancer (NSCLC) bearing KRAS G12C mutations who have undergone at least one line of systemic treatment. Jacobio has already submitted an application to the Centre for Drug Evaluation (CDE) for marketing of Glecirasib. The indication for this application aligns with the priority review orientation and focuses on providing second-line or above treatments for patients with late-stage or metastatic NSCLC carrying KRAS G12C mutations. #QMportfolio #QMhealthcare #JacobioPharma #Glecirasib #PriorityReview #NMPA #LungCancerTreatment #NSCLC

Ahead of print Oridonin attenuated human PC-3 cell activity by modulating the Wnt/β-catenin signaling Prostate cancer (PC) prevention is effectively achieved through its inhibition. Oridonin (ORD), an active diterpenoid isolated from Rabdosia rubescens, has been shown to have an inhibitory effect on PC cells, although its impact on PC is unknown. The present work investigated the actions and probable mechanisms of ORD on cellular proliferation, apoptosis, PC, and the wingless-type MMTV integration site family member 2 (Wnt)/β-catenin signaling pathway using the androgen-independent PC-3 cell line. https://lnkd.in/dSsCW3zH

More psychopathy on spike-o-pathy. But the funniest thing here is that this paper shows that SARS-CoV-2 spike protein which is produced by the COVID virus affects p53. What Peter McCullough totally omits to say here that COVID infection produces higher viral loads, and therefore Spike protein than the mRNA vaccine itself. And that the production of such overtime in the case of vaccines is one that is transient and disappears extremely rapidly, while is maintained, of long duration and is linked with long-COVID post COVID infection, something not seen in mRNA vaccines. Sorry for the McCullough Foundation , but you can’t have both ways. And you can’t lie anymore especially by using this pre-print paper, not peer-reviewed, and potentially that might never light of publication. But meanwhile, such paper shows that COVID infection itself would be, if you believe the lies of Peter McCullough ( more of such, here again), would trigger rise in cancers post infection itself to a greater extent than the mRNA vaccines themselves. Funny that the numbers of cancer cases in either situations, don’t support such conspiracy theory at all. It showed that delays in screening, diagnosis and cancer pushed more advanced cases through and we are sadly dealing with such now.

Check out our new preprint entitled "NQO1-responsive Prodrug for in Cellulo Release of Cytochalasin B as Cancer Cell-targeted Migrastatic".

Exploring the biological function of extracellular vesicles in prostate cancer and their clinical use as diagnostic and prognostic biomarkers: in their latest review article, Patrizia Limonta, Fabrizio Fontana at Università degli Studi di Milano and collaborators presented an overview of the role of EVs in prostate cancer, emphasising both their biological functions and clinical significance. Specifically, the study highlights the oncogenic role of EVs in mediating interactions within the prostate cancer microenvironment and facilitating the horizontal transfer of metastatic traits and drug resistance between prostate cancer cells https://lnkd.in/ga_3VfSv They pointed out that EV heterogeneity remains a major obstacle for biomarker discovery. Current bulk population-based methods for vesicle isolation and classification often fall short in delivering clinically relevant insights. An article co-authored by Sara Marchesi, Gaia Giannitti and Lavinia Casati #extracellularvesicles #exosomes #prostatecancer #liquidbiopsy #biomarkers #Vesiculab